(Q46477585)

22 December 2017

title

A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies (English)

1 reference

22 December 2017

main subject

phase I clinical trial

0 references

author name string

John F Gerecitano

1

1 reference

22 December 2017

Joe J Stephenson

2

1 reference

22 December 2017

Nancy L Lewis

3

1 reference

22 December 2017

Anna Osmukhina

4

1 reference

22 December 2017

Jianguo Li

5

1 reference

22 December 2017

Kaida Wu

6

1 reference

22 December 2017

Zhiping You

7

1 reference

22 December 2017

Dennis Huszar

8

1 reference

22 December 2017

Jeffrey M Skolnik

9

1 reference

22 December 2017

Gary K Schwartz

10

1 reference

22 December 2017

publication date

22 May 2012

1 reference

22 December 2017

Investigational New Drugs

published in

1 reference

22 December 2017

volume

31

1 reference

22 December 2017

issue

2

1 reference

22 December 2017

page(s)

355-362

1 reference

22 December 2017

Analysis of the kinesin superfamily: insights into structure and function

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9821-Y

Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9821-Y

Inhibition of a mitotic motor protein: where, how, and conformational consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9821-Y

Kinesin motor proteins as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9821-Y

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9821-Y

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9821-Y

A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9821-Y

Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9821-Y

A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors

21 January 2018

1 reference

12 December 2020

Cloning by differential screening of a Xenopus cDNA that encodes a kinesin-related protein

1 reference

12 December 2020

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

1 reference

12 December 2020

A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors

1 reference

12 December 2020

10.1007/S10637-012-9821-Y

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017